CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, SIRT1 inhibition had no significant effect on normal CD34+ cells proliferation and apoptosis, thus introducing SIRT1 inhibition as a possible new frontier for eliminating CML-LSCs.